Noemi  Kedei, M.D.
Noemi Kedei, M.D.
Staff Scientist

Center for Cancer Research
National Cancer Institute

Building 37, Room 4048
Bethesda, MD 20892
301-496-2948

Dr. Kedei's research focuses on understanding the factors contributing to the interaction of both synthetic ligands and natural products with protein kinase C (PKC), a validated anti-cancer target, and with other members of the PKC superfamily. A key question is to determine the mechanisms underlying the diverse biological responses to these ligands. Current efforts are directed at characterizing synthetic bryostatin derivatives termed bryologues. Bryostatin, while binding to and activating PKC, paradoxically antagonizes the responses of typical PKC ligands. Dr. Kedei seeks to define the structural features of bryostatin that determine this behavior and to trace the downstream mechanisms that account for the antagonism. Twin goals of the project are to develop structurally simplified bryostatin analogs and to identify those cancer subtypes in which the unique mechanism of bryostatin action would be predicted to have therapeutic benefit.

Areas of Expertise
ligands, anti-cancer targeting

Dr. Kedei's research focuses on understanding the factors contributing to the interaction of both synthetic ligands and natural products with protein kinase C (PKC), a validated anti-cancer target, and with other members of the PKC superfamily. A key question is to determine the mechanisms underlying the diverse biological responses to these ligands. Current efforts are directed at characterizing synthetic bryostatin derivatives termed bryologues. Bryostatin, while binding to and activating PKC, paradoxically antagonizes the responses of typical PKC ligands. Dr. Kedei seeks to define the structural features of bryostatin that determine this behavior and to trace the downstream mechanisms that account for the antagonism. Twin goals of the project are to develop structurally simplified bryostatin analogs and to identify those cancer subtypes in which the unique mechanism of bryostatin action would be predicted to have therapeutic benefit.

Selected Publications
  1. Kedei N, Telek A, Michalowski AM, Kraft MB, Li W, Poudel YB, Rudra A, Petersen ME, Keck GE, Blumberg PM.
    Biochem. Pharmacol.. 85: 313-24, 2013. [ Journal Article ]
  2. Rahman GM, Shanker S, Lewin NE, Kedei N, Hill CS, Prasad BV, Blumberg PM, Das J.
    Biochem. J.. 451: 33-44, 2013. [ Journal Article ]
  3. Kortum RL, Rouquette-Jazdanian AK, Miyaji M, Merrill RK, Markegard E, Pinski JM, Wesselink A, Nath NN, Alexander CP, Li W, Kedei N, Roose JP, Blumberg PM, Samelson LE, Sommers CL.
    J. Immunol.. 190: 147-58, 2013. [ Journal Article ]
  4. Chen JQ, Heldman MR, Herrmann MA, Kedei N, Woo W, Blumberg PM, Goldsmith PK.
    Anal. Biochem.. 442: 97-103, 2013. [ Journal Article ]
  5. Kedei N, Lewin NE, Géczy T, Selezneva J, Braun DC, Chen J, Herrmann MA, Heldman MR, Lim L, Mannan P, Garfield SH, Poudel YB, Cummins TJ, Rudra A, Blumberg PM, Keck GE.
    ACS Chem. Biol.. 8: 767-77, 2013. [ Journal Article ]

Biography Dr. Kedei received her MD degree from University Medical School of Debrecen, Hungary. She worked as an assistant professor at the Department of Biochemistry and Molecular Biology, University Medical School of Debrecen. In 1999 Dr. Kedei joined the Molecular Mechanisms of Tumor Promotion Section, LCBG, as a postdoctoral fellow. Currently she continues to work with Dr. Peter M. Blumberg as a staff scientist.

Summary

Dr. Kedei's research focuses on understanding the factors contributing to the interaction of both synthetic ligands and natural products with protein kinase C (PKC), a validated anti-cancer target, and with other members of the PKC superfamily. A key question is to determine the mechanisms underlying the diverse biological responses to these ligands. Current efforts are directed at characterizing synthetic bryostatin derivatives termed bryologues. Bryostatin, while binding to and activating PKC, paradoxically antagonizes the responses of typical PKC ligands. Dr. Kedei seeks to define the structural features of bryostatin that determine this behavior and to trace the downstream mechanisms that account for the antagonism. Twin goals of the project are to develop structurally simplified bryostatin analogs and to identify those cancer subtypes in which the unique mechanism of bryostatin action would be predicted to have therapeutic benefit.

Areas of Expertise
ligands, anti-cancer targeting

Research

Dr. Kedei's research focuses on understanding the factors contributing to the interaction of both synthetic ligands and natural products with protein kinase C (PKC), a validated anti-cancer target, and with other members of the PKC superfamily. A key question is to determine the mechanisms underlying the diverse biological responses to these ligands. Current efforts are directed at characterizing synthetic bryostatin derivatives termed bryologues. Bryostatin, while binding to and activating PKC, paradoxically antagonizes the responses of typical PKC ligands. Dr. Kedei seeks to define the structural features of bryostatin that determine this behavior and to trace the downstream mechanisms that account for the antagonism. Twin goals of the project are to develop structurally simplified bryostatin analogs and to identify those cancer subtypes in which the unique mechanism of bryostatin action would be predicted to have therapeutic benefit.

Publications

Selected Publications
  1. Kedei N, Telek A, Michalowski AM, Kraft MB, Li W, Poudel YB, Rudra A, Petersen ME, Keck GE, Blumberg PM.
    Biochem. Pharmacol.. 85: 313-24, 2013. [ Journal Article ]
  2. Rahman GM, Shanker S, Lewin NE, Kedei N, Hill CS, Prasad BV, Blumberg PM, Das J.
    Biochem. J.. 451: 33-44, 2013. [ Journal Article ]
  3. Kortum RL, Rouquette-Jazdanian AK, Miyaji M, Merrill RK, Markegard E, Pinski JM, Wesselink A, Nath NN, Alexander CP, Li W, Kedei N, Roose JP, Blumberg PM, Samelson LE, Sommers CL.
    J. Immunol.. 190: 147-58, 2013. [ Journal Article ]
  4. Chen JQ, Heldman MR, Herrmann MA, Kedei N, Woo W, Blumberg PM, Goldsmith PK.
    Anal. Biochem.. 442: 97-103, 2013. [ Journal Article ]
  5. Kedei N, Lewin NE, Géczy T, Selezneva J, Braun DC, Chen J, Herrmann MA, Heldman MR, Lim L, Mannan P, Garfield SH, Poudel YB, Cummins TJ, Rudra A, Blumberg PM, Keck GE.
    ACS Chem. Biol.. 8: 767-77, 2013. [ Journal Article ]

Biography

Biography Dr. Kedei received her MD degree from University Medical School of Debrecen, Hungary. She worked as an assistant professor at the Department of Biochemistry and Molecular Biology, University Medical School of Debrecen. In 1999 Dr. Kedei joined the Molecular Mechanisms of Tumor Promotion Section, LCBG, as a postdoctoral fellow. Currently she continues to work with Dr. Peter M. Blumberg as a staff scientist.